Frontiers in Nutrition · 2023 · 15 citations · 25 references
MedicinePharmacotherapySurgeryClinical NutritionHuman NutritionMetabolic PhysiologyBody Composition ChangesDiabetes MellitusMetabolic SyndromeObesity ManagementWeight LossWeight ManagementBariatric Surgery Weight LossBody Composition MeasurementNutritional Counseling EducationObesity TreatmentPharmacotherapy After Bariatric SurgeryPharmacotherapy For Weight LossWeight Loss AnalysisWeight Loss Measurement
Background: Bariatric surgery (BS) represents the most effective therapy for obesity class III, or class II with at least one weight-related comorbidity. However, some patients have insufficient weight loss or clinically relevant weight regain after a successful primary procedure. This study aimed to assess the efficacy of liraglutide treatment on weight loss, body composition and improvement of metabolic syndrome (MS) in patients defined as poor responders after BS. Methods: ) who had been treated with BS and experienced a poor response, categorized as either IWL (insufficient weight loss) or WR (weight regain). All patients were prescribed pharmacological therapy with liraglutide and attended nutritional counseling. Anthropometric and clinical measurements, body composition and the presence of MS defined according to the ATP-III classification were evaluated before starting liraglutide and after 24 weeks of treatment. Results: After 24 weeks of treatment with liraglutide, the mean weight loss was 8.4% ± 3.6% with no difference between gender, bariatric procedure, or type of poor response (IWL or WR). A significant decrease in fat mass, free-fat mass and total body water was documented. After 24 weeks, patients presented significantly lowered fasting glucose, total cholesterol, triglycerides, AST and ALT. The prevalence of MS was reduced from 35% at baseline to 1.6% after 24 weeks. No patients discontinued the treatment during the study. Conclusion: In patients who experience poor response after BS, liraglutide is well tolerated and promotes significant weight loss, ameliorates cardiometabolic comorbidities, and reduces the prevalence of MS.
25
Ömer Toprak, Hüseyin Kurt, Yasin Sarı et al. · Kidney & Blood Pressure Research · 2017 · 29.7K citations · Full text
Medicine, Endocrinology, Nutrition +17
Evaluation Expert Panel on Detection · JAMA · 2001 · 26K citations
Medicine, Cardiology, Otolaryngology +10
European Guidelines for Obesity Management in Adults
Volkan Yumuk, Constantine Tsigos, Martin Fried et al. · Obesity Facts · 2015 · 3.4K citations · Full text
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
F. Xavier Pi‐Sunyer, Arne Astrup, Ken Fujioka et al. · New England Journal of Medicine · 2015 · 2.6K citations · Full text
Matthew J. Armstrong, Piers Gaunt, Guruprasad P. Aithal et al. · The Lancet · 2015 · 2.1K citations · Full text